| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2024/03/05 | 02 : 22 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/02/28 | 14 : 15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/02/27 | 07 : 28 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/02/27 | 07 : 28 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/02/27 | 07 : 26 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/02/27 | 07 : 26 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/02/22 | 22 : 50 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/02/22 | 22 : 45 | GlobeNewswire Inc. | Gracell Biotechnologies Acquisition Completed | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/02/20 | 22 : 22 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/02/20 | 21 : 45 | GlobeNewswire Inc. | Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/02/14 | 22 : 20 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/01/30 | 20 : 02 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/01/29 | 21 : 00 | GlobeNewswire Inc. | Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/01/18 | 06 : 30 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/01/09 | 06 : 01 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2024/01/09 | 00 : 06 | PR Newswire (US) | Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law Firm | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/12/26 | 22 : 12 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/12/26 | 20 : 44 | Dow Jones News | Gracell ADSs Take Flight Premarket on $1.2 Billion Takeover by AstraZeneca | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/12/26 | 17 : 05 | Dow Jones News | AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/12/26 | 16 : 01 | Business Wire | AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/12/26 | 16 : 00 | GlobeNewswire Inc. | Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/12/22 | 20 : 03 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/12/21 | 21 : 00 | GlobeNewswire Inc. | Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/12/19 | 06 : 00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/12/12 | 09 : 30 | GlobeNewswire Inc. | Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023 | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/11/29 | 20 : 18 | IH Market News | Amazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and More | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/11/29 | 04 : 59 | Dow Jones News | Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/11/27 | 22 : 00 | GlobeNewswire Inc. | Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/11/21 | 20 : 25 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 2023/11/16 | 22 : 00 | GlobeNewswire Inc. | Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit | NASDAQ:GRCL | Gracell Biotechnologies Inc |